U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multip
Go back to U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multip| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 63.07 +0.01 (0.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $63.06 | 52 Week High | $77.12 | |||
| Open | $63.09 | 52 Week Low | $49.03 | |||
| Day High | $63.40 | P/E | 40.95 | |||
| Day Low | $62.70 | EPS | $1.54 | |||
| Volume | 2,808,414 | |||||
